On Tuesday July 28, the Arkansas State Board of Pharmacy suspended enforcement of a 2025 Arkansas law, Act 630, two months after a federal […]
Following court decision, Arkansas will not enforce Act 630 on drug distribution Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
The new BIO-Norstella State of Emerging Biotech report finds venture capital has returned, pipelines are becoming more efficient, and emerging biotech companies continue to
BIO 2026: As capital returns, focus on quality over quantity Read More »
From drug discovery to target identification, biotech leaders explored where AI is delivering results today, why data quality matters, and how companies can successfully
BIO 2026: Where AI is delivering – and where biotech must go next Read More »
“AI systems will likely have a central role over the next several years in almost every component of the biotech ecosystem,” says Joe Franklin,
BIO 2026: What to know about the AI Summit Read More »
Patient advocates are praising Virginia Gov. Abigail Spanberger’s May 19 veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271), arguing
Patient groups praise Virginia PDAB veto Read More »
